Valuation: Inotiv, Inc.

Market Cap 387K 339K 315K 289K 546K 37.3M 552K 3.75M 1.47M 18.28M 1.45M 1.42M 63.11M P/E 2024
-0.41x
P/E 2025 -0.69x
Enterprise Value 438M 384M 356M 327M 617M 42.18B 625M 4.24B 1.66B 20.67B 1.64B 1.61B 71.37B EV / Sales 2024
0.95x
EV / Sales 2025 0.95x
Free-Float
91.39%
Yield 2024 *
-
Yield 2025 -
1 week 0
Extreme 0
0.02
1 month 0
Extreme 0
0.03
Current year 0
Extreme 0
0.65
1 year 0
Extreme 0
2.44
3 years 0
Extreme 0
11.42
5 years 0
Extreme 0
60.66
10 years 0
Extreme 0
60.66
Manager TitleAgeSince
Chief Executive Officer 67 12/01/2019
Director of Finance/CFO 61 06/03/2020
Compliance Officer 49 23/10/2023
Director TitleAgeSince
Chairman 71 26/03/2024
Director/Board Member 71 24/01/2023
Director/Board Member 63 14/03/2024
Date Insider Type Main position Quantity % Market Cap.
7/19/26 A Others

Director

-729,626 2.0913%
7/19/26 A Others

Controller/Auditor

-36,623 0.1050%
7/19/26 A Others

Chief Executive Officer

-1,361,215 3.9017%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 387K
-4.33%-8.26%-3.89%+9.87% 48.5B
+1.61%-0.91%+377.07%+584.68% 38.97B
+2.61%+3.96%+9.16%+61.36% 35.43B
-1.12%-2.99%+26.84%-11.67% 33.65B
-0.58%-0.69%-0.56%+30.30% 26.58B
+1.37%-3.90% - - 16.82B
+0.71%-0.84%+72.13%+116.76% 15.18B
+0.11%+0.61%+10.04%+13.92% 13.89B
+0.26%-0.80%+19.33%-32.25% 12.76B
Average +0.05%-0.84%+63.76%+96.62% 24.18B
Weighted average by Cap. -0.32%-1.00%+76.45%+121.81%

Financials

2024 2025
Net sales 491M 430M 399M 367M 692M 47.26B 700M 4.76B 1.86B 23.16B 1.84B 1.8B 79.97B 513M 450M 417M 383M 723M 49.41B 732M 4.97B 1.95B 24.21B 1.93B 1.88B 83.61B
Net income -108M -95.05M -88.07M -81.06M -153M -10.44B -155M -1.05B -411M -5.12B -407M -398M -17.67B -68.62M -60.15M -55.73M -51.3M -96.73M -6.61B -97.9M -665M -260M -3.24B -258M -252M -11.18B
Net Debt 424M 371M 344M 317M 597M 40.8B 604M 4.11B 1.61B 20B 1.59B 1.56B 69.05B 438M 384M 355M 327M 617M 42.14B 624M 4.24B 1.66B 20.65B 1.64B 1.61B 71.31B
Logo Inotiv, Inc.
Inotiv, Inc. is a contract research company engaged in providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries, as well as academia and government clients. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. It operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through DSA segment, it supports the discovery, nonclinical development and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through RMS segment, it offers access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas.
Employees
1,996
Date Price Change Volume
17/07/26 $0.0111 -26.00% 243,786
16/07/26 $0.0150 +32.74% 70,600
15/07/26 $0.0113 -13.08% 630,714
14/07/26 $0.0130 -26.97% 325,742
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. NOTVQ Stock